June 2011- Volume 7, Issue 6

June 2011

In this Issue

Contract Services

Controlling their own destiny

Controlling their own destiny

Nautic Partners acquires Omnicare’s CRO arm

Entrée into the Orient

Entrée into the Orient

Mitsui acquires MBS and expands geographic base

Serving up ‘plate-to-patient’ fare

Serving up ‘plate-to-patient’ fare

Quotient Bioresearch and KWS BioTest partner on end-to-end anti-infectives screening

A public-private partnership

A public-private partnership

Paragon, UMB and Life Technologies to develop stem-cell therapies

Research & Development

What's Next(erone) for Baxter?

What's Next(erone) for Baxter?

Pharma giant acquires Ligand partner Prism to bring Nexterone, an anti-arrhythmic agent, to market

BBB and beyond

BBB and beyond

Lilly, Medtronic collaborate on crossing blood brain barrier to combat Parkinson’s disease

Striking a ‘cord’ with spinal injuries

Striking a ‘cord’ with spinal injuries

InVivo, UMiami collaboration to combine SCI technologies for treatment

Right fit, right time

Right fit, right time

Alkermes and Élan Drug Technologies announce $960 million merger, creating leader in CNS therapeutics

One for the history books

One for the history books

In its largest acquisition to date, Johnson & Johnson acquires medical device maker Synthes for $21.3 billion, creating the world’s largest orthopedics business

Feature

Look at what’s new in D.C.

Look at what’s new in D.C.

Program for 2011 BIO International Convention seeks to provide attendees with a well-rounded knowledge base they can use to advance business objectives

Omics & Systems Biology

Taking the path of least resistance

Taking the path of least resistance

Gene-editing collaboration to fight EGFR- targeted therapy resistance

Surf’s up for microRNAs

Surf’s up for microRNAs

Regulus Therapeutics, UCSD collaborate on angiogenic disease research utilizing microRNA technology

Wet or dry, hope for the eye

Wet or dry, hope for the eye

Tufts researchers find protein CD59 is key to slowing age-related macular degeneration

Creating cancer for the greater good

Creating cancer for the greater good

Researchers make normal stem cells into cancer stem cells and achieve important insights into triple-negative breast cancer

Playing by the Rules

Playing by the Rules

Myriad acquires Austin-based Rules- Based Medicine for $80 million, boosting capabilities in biomarker discovery

Diagnostics

In NARMS way

In NARMS way

Magellan Biosciences and miacom diagnostics partner to speed up identification of pathogens, streamline lab workflow and enable better treatment decisions

Alzheimer’s disease: First steps to stem the epidemic

Alzheimer’s disease: First steps to stem the epidemic

AD guidelines updated for the first time in decades; NIH-supported revision also proposes staging of disease, potential use of biomarkers

A wide spectrum narrows

A wide spectrum narrows

SynapDx licenses autism diagnostic discoveries from Children’s Hospital Boston

Multiplex makes for a magnetic attraction

Multiplex makes for a magnetic attraction

Applied BioCode announces strategic technology partnership, license agreement with EraGen Biosciences

Instruments & Informatics

Imaging is everything

Imaging is everything

GE Healthcare to acquire cellular imaging company Applied Precision as part of its life-science expansion plans

Avantor acquires POCH from Kulczyk Holding

Avantor acquires POCH from Kulczyk Holding

Acquisition of Poland’s leading performance materials supplier will expand Avantor’s laboratory offering and manufacturing footprint in Eastern Europe

License to drive

License to drive

Sigma Life Science commercializes technology from King’s College London that eases miRNA target identification bottlenecks

The future of work

The future of work

Cognizant, Eagle Genomics work with Pistoia Alliance to develop cloud-based platform to streamline sequencing services

Two’s a cloud

Two’s a cloud

PerkinElmer acquires Geospiza, a leading developer of cloud computing software

Editor's Focus

Will open access open a Pandora’s box for scientific journals?

Will open access open a Pandora’s box for scientific journals?

Should the content in scientific journals be made available to the public? There are unintended consequences to opening up copyrighted material, as evidenced by the many challenges facing the journalism business since Al Gore 'invented' the Internet.

Commentary

New tools take time

New tools take time

It’s been a rough first half in 2011, but beneath the noise, much progress is being made, and the last five years have been a lot more productive than we take time to realize.

Guest Commentary: Generating more knowledge from data and more value from studies

Guest Commentary: Generating more knowledge from data and more value from studies

The nature of drug discovery and development remains an information-rich endeavor, and in order to increase success rates, we must make better use of our data—and our information science experts.

Global News

Back to school

Back to school

Swiss developer Debiopharm and Yale in licensing deal on inhibitor for autoimmune and inflammatory diseases

Taking cancer to TASQ

Taking cancer to TASQ

Active Biotech and Ipsen partner on Tasquinimod TASQ compound in uro-oncology

Once-in-a-decade breakthrough

Once-in-a-decade breakthrough

Alnylam and Precision NanoSystems form RNAi delivery collaboration

A helping hand in India

A helping hand in India

Swedish pharma Karo Bio and Indian pharma Alkem Laboratories Ltd. to develop eprotirome for dyslipidemia
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue